Icon

Symtuza - (800 mg/150 mg/ 200 mg/10 mg ; Tablets)

Darunavir, Cobicistat, Emtricitabine, Tenofovir Alafenamide Janssen Pharma
800 mg/150 mg/ 200 mg/10 mg ; Tablets
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
None None
SYMTUZA is a four-drug combination of darunavir (DRV), a human immunodeficiency virus (HIV-1) protease inhibitor, cobicistat (COBI), a CYP3A inhibitor, and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, and is indicated as a complete regimen for the treatment of HIV-1 infection in adults: • who have no prior antiretroviral treatment history or • who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir.
Yes
****** ** *** ****** ****** *** ******* '*** *** '*** ** ******* *******. ***** ******* ** *** *** ****** ****** ** **** *******. **** ***** *** ****** ***** ** ************ ** ****** '***. ** ** ***'* ****** ******* ****** ** ** ****** *** **, ****.
Symtuza Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13
***** ******* *** ********* *** ********* *** ********* *** ********* *** ********* ******* ******* ****** ************/ ******** ********* ******* ****** ************/ ******** ********* ******* ****** ******** ****** ****** ******** ****** *** *********
****** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* ******* ******* ******* ****** *** ****** ******** ****** ****** ******** ****** ****** ******** ******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** / ********* ***** **, **** ********* **** / ******* **** *** ****** *** ****
****** ** / ** *** **, **** ******* ***** ********* ************ **** ******* *** **** *** *** ****
  1. *** **, **** : * **** ** *** ***** *** ***** ** * *** *******.
  2. *** *, **** : ***** ******** ****** (****** ****** ** ******* '*** *** '***) ********* *** **** ** ****** *** * ******.
  3. *** **, **** : ****** **** ***** **** ******* '*** *** '*** **** ******** ** *** **, ****.
  4. *** **, **** : ****** **** ***** ( ******* **** ***- *** ****** ** *** *** *** **** *******) **** ******* '***, '***, '*** *** '***.
  5. *** **, **** : ****** ******** ****** ** *** ****-** ****** **** ******* '***, '***, '***, '***, '*** *** '***
  6. *** **, **** : ****** **** ****** **** ************ ** ******* '***, '***, '***, '***, *** '***. ****** ***** * ******** **** **** ******* '*** *** '***.
  7. *** *, **** : ****** ******** ********* ********* ***-** ******* '*** *** '*** ******* *****. ***** ****** ** ********** ******* ****** ** ****** '*** *** '***, *** **** ****** ****** ****** *** **, ****
  8. *** **, **** : ****** *** ****** ******* ****** ** ******* ********** ********* ****** '*** ******** ****** ****** *** ***** *** ********** *.*. ****** *** *** ****** '***. ** *** ****** '***, ****** ****** ** ************, *** *** ******** ********* ******* *******. ****** ******** ********* ********* ***-** ******* '***, '*** *** '***
  9. *** **, **** : ****** *** ***** ******* ********** **** ******* '*** *** '***. *** ********** ** ***** ******* ****** *******.
  10. *** *, **** : ****** ***** * *** **** ******* ***** *** *** (*** *** **-********** *** ***** ****) **** ************ ** ******* '*** *** '***. *** ********** ** *** ******** *****, *****'* ************ *********** ****** *** ****.
  11. *** **, **** : ****** *** ****** ******* ********** **** ********* ******* ** ******* *****.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.